Pediatric Pulmonary Vascular Disease

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

Liezl T. Domingo, D. Dunbar Ivy, Steven H. Abman, Alicia M. Grenolds, James T. MacLean, J. A. Breaux, Katie J. Minford, Benjamin S. FrankUniversity of Utah. University of Colorado.United States Frontiers in PediatricsFront Pediatr 2022; 10: DOI: 10.3389/fped.2022.1014922 AbstractIntroduction: Riociguat, an oral soluble guanylate cyclase stimulator, has been approved for use in adults with pulmonary arterial hypertension […]

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide Read More »

High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease: A report of two cases

Yoshie Fukusawa, Hidenori Yamamoto, Miharu Ito, Akiko Saito, Kiyotaka Go, Yoshihito Morimoto, Kazushi Yasuda, Yoshiaki Sato, Masahiro Hayakawa, Taichi KatoNagoya University and Nagoya University Hospital. Ogaki Municipal Hospital. Japanese Red Cross Nagoya Daichi Hospital. Aichi Child Health and Medical General Center.Japan Frontiers in Pediatrics. Pediatric Cardiology SectionFront Pediatr 2023; 11: DOI: 10.3389/fped.2023.1116434 AbstractPulmonary hypertension (PH) with

High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease: A report of two cases Read More »

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension

Elizabeth Colglazier, Leah Stevens, Claire Parker, Hythem M. Nawaytou, Elena K. Amin, Jasmine Becerra, Martina Steurer, Jeffrey R. FinemanUniversity of California San FranciscoUnited States Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12159 AbstractDespite the increase in therapeutic options, parenteral prostacyclins remain the cornerstone in the medical management of pulmonary arterial hypertension (PAH). While the use of parenteral

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension Read More »

Building a dedicated pediatric pulmonary hypertension program: A consensus statement from the pediatric pulmonary hypertension network

Stephanie S. Handler, Nidhy P. Varghese, Erika B. Rosenzweig, Delphine Yung, Usha Krishnan, Elise Whalen, Angela Bates, Catherine M. Avitabile, Emma O. Jackson, Russel Hirsch, Jeffrey Fineman, Steven H. Abman The Pediatric Pulmonary Hypertension Network (PPHNet)United States and Canada Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12031 AbstractPediatric pulmonary hypertension (PH) is a severe, life-threatening disease associated

Building a dedicated pediatric pulmonary hypertension program: A consensus statement from the pediatric pulmonary hypertension network Read More »

Multifactorial pulmonary hypertension in infantile scimitar syndrome

Damien Bonnet, Isabelle Szezepanski, Christophe Delacourt, Sophie Malkezadeh-Milani, Maryline LévyHôpital Necker-Enfants Malades, AP-HP, Université de ParisFrance Archives of Cardiovascular DiseaseArch Cardiovasc Dis 2022; 115: 142-150DOI: 10.1016/j.acvd.2022.01.004 AbstractBackground: Pulmonary hypertension in infantile scimitar syndrome is highly prevalent at diagnosis, and has a multifactorial origin.Aims: To analyse the constellation of anatomical anomalies and initial physiology, and their contribution to

Multifactorial pulmonary hypertension in infantile scimitar syndrome Read More »

Respiratory viruses and postoperative hemodynamics in patients with unrestrictive congenital cardiac communications: a prospective cohort study

Kelly C. O. Abud, Clarisse M. Machado, Lucy S. Vilas Boas, Nair Y. Maeda, Eloisa S. Carvalho, Maria Francilene S. Souza, Paula V. Gaiolla, Claudia R. P. Castro1 Juliana Pereira, Marlene Rabinovitch, Antonio Augusto LopesUniversity of São Paulo School of Medicine, Pró-Sangue Foundation, Stanford University School of MedicineBrazil and United States European Journal of Medical

Respiratory viruses and postoperative hemodynamics in patients with unrestrictive congenital cardiac communications: a prospective cohort study Read More »

Pulmonary-to-Systemic Arterial Shunt to treat Children with Severe Pulmonary Hypertension

R. Mark Grady, Matthew W. Canter, Fei Wan, Anton A. Shmalts, Ryan D. Coleman, Maurice Beghetti, Rolf M. F. Berger, Maria J. del Cerro Marin, MD, Scott E. Fletcher, Russel Hirsch, Tilman Humpl, D. Dunbar Ivy, Edward C. Kirkpatrick, Thomas J. Kulik, Marilyne Levy, Shahin Moledina, Delphine Yung, Pirooz Eghtesady, Damien BonnetWashington University, A.N. Bakoulev

Pulmonary-to-Systemic Arterial Shunt to treat Children with Severe Pulmonary Hypertension Read More »

Prematurity and Pulmonary Vein Stenosis: The Role of Parenchymal Lung Disease and Pulmonary Vascular Disease

Shilpa Vyas-Read, Nidhy P. Varghese, Divya Suthar, Carl Backes, Satyan Lakshminrusimha, Christopher J. Petit, Philip T. LevyEmory University and Children’s Healthcare of Atlanta. Baylor College of Medicine and Texas Children’s Hospital. Ohio State University and Nationwide Children’s Hospital. University of California Davis. Harvard University and Boston Children’s Hospital.United States Children (Basel)Children 2022; 9: DOI: 10.3390/children9050713 AbstractPulmonary

Prematurity and Pulmonary Vein Stenosis: The Role of Parenchymal Lung Disease and Pulmonary Vascular Disease Read More »

Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis

Jay D. Patel, Michael Briones, Mansi Mandhani, Shannon Jones, Divya Suthar, Rosemary Gray, Joelle Pettus, Courtney McCraken, Amanda Thomas, Christopher J. PetitEmory University and Children’s Healthcare of AtlantaUnited States Journal of the American College of CardiologyJ Am Coll Cardiol 2021; 77: 2807-2818DOI: 10.1016/j.jacc.2021.04.013 AbstractBackground: Anatomic interventions for pulmonary vein stenosis (PVS) in infants and children have been

Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis Read More »

The vascular phenotype of BPD: new basic science insights-new precision medicine approaches

Wojciech Durlak, Bernard ThébaudUniversity of Ottawa. Jagiellonian University Medical College. Poland and Canada Pediatric ResearchPediatr Res 2022; DOI: 10.1038/s41390-022-02428-7 AbstractBronchopulmonary dysplasia (BPD) is the most common complication of preterm birth. Up to 1/3 of children with BPD develop pulmonary hypertension (PH). PH increases mortality, the risk of adverse neurodevelopmental outcome and lacks effective treatment. Current vasodilator

The vascular phenotype of BPD: new basic science insights-new precision medicine approaches Read More »

Scroll to Top